drugset / Trial / NCT06674941
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and to assess the PK of teprotumumab delivered by syringe pump and by an injection device in non-Japanese participants.
Timeline
- Start
- 2023-03-24
- Primary completion
- 2023-11-14
- Completion
- 2023-11-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teprotumumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.